IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v37y2019i1d10.1007_s40273-018-0752-0.html
   My bibliography  Save this article

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

Author

Listed:
  • Min Huang

    (Merck & Co., Inc.)

  • M. Catherine Pietanza

    (Merck & Co., Inc.)

  • Ayman Samkari

    (Merck & Co., Inc.)

  • James Pellissier

    (Merck & Co., Inc.)

  • Thomas Burke

    (Merck & Co., Inc.)

  • Sheenu Chandwani

    (Merck & Co., Inc.)

  • Fansen Kong

    (Merck & Co., Inc.)

  • A. Simon Pickard

    (Second City Outcomes Research)

Abstract

Objectives Pembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1)–positive tumors in the first-line setting in KEYNOTE (KN)-024 and in those previously treated in KN010. The objective of this analysis was to assess the benefit–risk of pembrolizumab in terms of quality-adjusted survival amongst patients in these trials. Methods The Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis was used to compare treatments. Survival time was partitioned into three health states: with toxicity before disease progression, without toxicity before disease progression, and disease progression until death. Health state utilities were estimated using EuroQol-5 Dimensions, 3 Levels (EQ-5D-3L) data collected in the trials. Q-TWiST was calculated as the utility-weighted sum of the mean health state durations. Trial data analyzed included the primary analysis and subsequent data cutoffs. The base-case analysis was based on the most recent analysis of the trials. Results Patients randomized to pembrolizumab had 2.49 months greater Q-TWiST (P value

Suggested Citation

  • Min Huang & M. Catherine Pietanza & Ayman Samkari & James Pellissier & Thomas Burke & Sheenu Chandwani & Fansen Kong & A. Simon Pickard, 2019. "Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer," PharmacoEconomics, Springer, vol. 37(1), pages 105-116, January.
    • Handle: RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0752-0
    DOI: 10.1007/s40273-018-0752-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-018-0752-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-018-0752-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0752-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.